KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) EBIT Margin (2019 - 2025)

Royalty Pharma (RPRX) has disclosed EBIT Margin for 7 consecutive years, with 62.44% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 154.0% to 62.44% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 65.58% through Dec 2025, up 848.0% year-over-year, with the annual reading at 65.58% for FY2025, 848.0% up from the prior year.
  • EBIT Margin hit 62.44% in Q4 2025 for Royalty Pharma, down from 70.11% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 134.23% in Q2 2021 to a low of 85.31% in Q4 2022.
  • Historically, EBIT Margin has averaged 52.44% across 5 years, with a median of 50.96% in 2021.
  • Biggest five-year swings in EBIT Margin: plummeted -11196bps in 2022 and later surged 18814bps in 2023.
  • Year by year, EBIT Margin stood at 26.65% in 2021, then plummeted by -420bps to 85.31% in 2022, then skyrocketed by 221bps to 102.82% in 2023, then plummeted by -41bps to 60.9% in 2024, then grew by 3bps to 62.44% in 2025.
  • Business Quant data shows EBIT Margin for RPRX at 62.44% in Q4 2025, 70.11% in Q3 2025, and 36.26% in Q2 2025.